A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1112 participants.

Also called NCT05056727

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,112 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05056727
  • EudraCT 2021-001911-96
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Bulgaria, Canada, China, India, Italy, Japan, Malaysia, Mexico, Philippines, Poland, Puerto Rico, Russia, Spain, Taiwan, Thailand, Türkiye, Ukraine, Vietnam (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05056727. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-30 (actual); primary completion 2024-02-07 (actual). Results posted on 2026-01-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
Acronym
STABILIZE-CKD
Condition
Renal Insufficiency, Chronic
Condition
Hyperkalemia
Intervention (Drug)
Sodium Zirconium Cyclosilicate (SZC)
Intervention (Drug)
Placebo
Intervention (Drug)
Lisinopril
Intervention (Drug)
Valsartan
Intervention (Drug)
Irbesartan
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct05056727
Content hash
4c6e9d712ca33a54d29b6bc14baca93a2e8480b778027d3a21270dbd6f148eb1